Head-to-head · WeighScore
Harbor vs Revel RX
By GLP-1 ScorecardUpdated
Score comparison
Revel RX has the higher recorded score — 77.3/100 to 72/100.
Revel RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revel Rx advertises the same monthly price across doses and no separate membership fee. Its refund policy still refers to canceling a subscription.
Before you choose
Before comparing the headline prices, the Harbor review and the Revel RX review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Harbor vs RxPros and Lean Meds vs Revel RX compare each of them with another graded program, and the list of alternatives to Harbor ranks the programs closest to Harbor on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Belle Health review covers one graded close to these two, at 73.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Harbor | Revel RX |
|---|---|---|
| WeighScore | 72/100 | 77.3/100 |
| Grade | C | C+ |
| Site position | #94 | #48 |
| Semaglutide | $99/mo (starting dose, compounded) | $89/mo (advertised all doses, compounded) |
| Tirzepatide | $149/mo (starting dose, compounded) | $155/mo (advertised all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
- LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
- 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
- 12-Month Money Back Guarantee if you don't reach your weight-loss goal
- HSA/FSA eligible; no hidden fees, no insurance billed
What to consider
- Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
- Dietitian support offered only post-program (maintenance phase), not during active treatment
- State-specific consultation types vary; nationwide availability unconfirmed for all states
- No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
- Newer brand; success rate and member counts are on-site claims, not third-party verified
Strengths
- Publishes prices for both compounded medications
- Advertises clinician review and included shipping
- Provides written instructions for canceling before shipment
What to consider
- The refund policy treats charged orders already handed to the carrier as final
- No dispensing pharmacy assignment or state eligibility was verified for an individual order
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.